CRIS Curis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRIS

Price (delayed)

$0.5058

Market cap

$48.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.61

Enterprise value

$33.15M

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of ...

Highlights
CRIS's debt is down by 22% YoY and by 6% from the previous quarter
CRIS's quick ratio is up by 20% since the previous quarter
The net income is down by 25% year-on-year but it is up by 3.9% since the previous quarter
Curis's EPS has decreased by 22% YoY but it has increased by 4.7% QoQ
The equity has contracted by 49% YoY and by 16% from the previous quarter
The revenue has declined by 4.6% year-on-year and by 2.4% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.curis.com
Peers: EXEL INFI EBS BMY

Key stats

What are the main financial stats of CRIS
Market
Shares outstanding
96.62M
Market cap
$48.87M
Enterprise value
$33.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.05
Price to sales (P/S)
4.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.26
Earnings
Revenue
$10.16M
EBIT
-$56.67M
EBITDA
-$55.28M
Free cash flow
-$54.75M
Per share
EPS
-$0.61
Free cash flow per share
-$0.59
Book value per share
$0.48
Revenue per share
$0.11
TBVPS
$1.07
Balance sheet
Total assets
$108.85M
Total liabilities
$62.3M
Debt
$3.94M
Equity
$46.55M
Working capital
$82.11M
Liquidity
Debt to equity
0.08
Current ratio
9.2
Quick ratio
8.85
Net debt/EBITDA
0.28
Margins
EBITDA margin
-544%
Gross margin
97.5%
Net margin
-557.7%
Operating margin
-521.7%
Efficiency
Return on assets
-45.2%
Return on equity
-94.3%
Return on invested capital
-67.8%
Return on capital employed
-57.3%
Return on sales
-557.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRIS stock price

How has the Curis stock price performed over time
Intraday
-1.02%
1 week
-9.68%
1 month
-20.22%
1 year
-80.69%
YTD
-8.04%
QTD
-8.04%

Financial performance

How have Curis's revenue and profit performed over time
Revenue
$10.16M
Gross profit
$9.91M
Operating income
-$53.02M
Net income
-$56.67M
Gross margin
97.5%
Net margin
-557.7%
CRIS's operating margin is down by 32% year-on-year
CRIS's net margin is down by 31% YoY
Curis's operating income has decreased by 26% YoY but it has increased by 4.2% QoQ
The net income is down by 25% year-on-year but it is up by 3.9% since the previous quarter

Growth

What is Curis's growth rate over time

Valuation

What is Curis stock price valuation
P/E
N/A
P/B
1.05
P/S
4.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.26
Curis's EPS has decreased by 22% YoY but it has increased by 4.7% QoQ
The equity has contracted by 49% YoY and by 16% from the previous quarter
The price to book (P/B) is 38% lower than the last 4 quarters average of 1.7
CRIS's price to sales (P/S) is 78% lower than its 5-year quarterly average of 21.1 and 54% lower than its last 4 quarters average of 10.2
The revenue has declined by 4.6% year-on-year and by 2.4% since the previous quarter

Efficiency

How efficient is Curis business performance
CRIS's return on equity has dropped by 122% year-on-year and by 14% since the previous quarter
The company's return on assets has shrunk by 76% YoY and by 6% QoQ
The ROIC has decreased by 40% YoY and by 5% from the previous quarter
Curis's return on sales has decreased by 31% YoY

Dividends

What is CRIS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRIS.

Financial health

How did Curis financials performed over time
The company's total assets is 75% higher than its total liabilities
The company's total assets fell by 33% YoY and by 11% QoQ
The current ratio rose by 20% since the previous quarter
CRIS's debt is 92% less than its equity
The equity has contracted by 49% YoY and by 16% from the previous quarter
The debt to equity has increased by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.